Results 121 to 130 of about 4,710,977 (252)

Short‐Term Response to Biologic Therapy in Psoriatic Arthritis Is Not Influenced by Disease Duration at Initiation of Therapy

open access: yesArthritis Care &Research, EarlyView.
Objective We aimed to determine whether the short‐term response to biologics in biologic‐naive psoriatic arthritis (PsA) is better in patients initiating biologic treatment early in the disease course. Methods Patients with PsA who started on biologic therapy from the year 2000 to 2025 were included for analysis.
Sung Min Cho   +4 more
wiley   +1 more source

Health damage cost of automotive air pollution: Cost benefit analysis of fuel quality upgradation for Indian cities. [PDF]

open access: yes
The paper has analysed the economic implication of judicial activism of the apex court of India in the regulation of automotive air pollution. It estimates the health damage cost of urban air pollution for 35 major urban agglomerations of India arising ...
Sengupta, Ramprasad, Mandal, Subrata
core  

Impact of Six‐Month Monitoring Compared to Three‐Month Monitoring of Laboratories During Methotrexate Therapy

open access: yesArthritis Care &Research, EarlyView.
Objective To evaluate whether extending the American College of Rheumatology–recommended monitoring interval for complete blood count and liver function tests in patients receiving methotrexate (MTX) affects timely detection of medication‐related toxicity.
Spencer Simko   +4 more
wiley   +1 more source

The Development of Rheumatoid Arthritis–Specific Ambulatory Care–Sensitive Conditions: Results of a Consensus Process

open access: yesArthritis Care &Research, EarlyView.
Objective Ambulatory care–sensitive conditions (ACSCs) serve as indicators of access, quality, and performance of the health system. This study aimed to determine rheumatoid arthritis (RA)‐specific ACSCs for use in the evaluation of care system access and quality.
Kara Irwin   +7 more
wiley   +1 more source

How Well Does the U.S. Government Do Cost-Benefit Analysis? [PDF]

open access: yes
To make prudent recommendations for improving the use of cost-benefit analysis in policy settings, some measures of how well it is actually done are essential.
Hahn, Robert W., Dudley, Patrick M.
core  

Beyond Visual Scoring: Computational Computed Tomography Analysis for High‐Resolution Computed Tomography–Based Quantification of Interstitial Lung Disease in Inflammatory Rheumatic Disease

open access: yesArthritis Care &Research, EarlyView.
Interstitial lung disease (ILD) is a significant cause of morbidity and mortality in patients with inflammatory rheumatic disorders (IRDs). High‐resolution computed tomography (HRCT) is widely considered the gold standard for the noninvasive assessment of ILD; however, its interpretation is constrained by substantial interobserver variability and the ...
Alexander Pfeil   +7 more
wiley   +1 more source

Cost- benefit analysis of the location of new forest land [PDF]

open access: yes
In this paper we show how cost-benefit analysis can be used as a decision support mechanism for the location of new (urban) forest land, starting from the multifunctional role of these new forests.
Ellen Moons
core  

Facial Cosmetic Therapy Use Among Patients With Systemic Sclerosis: An Australian Cohort Study

open access: yesArthritis Care &Research, EarlyView.
Objective Systemic sclerosis (SSc) is associated with numerous facial manifestations for which patients may engage in cosmetic therapies. It is unclear how patients with SSc use these therapies. This study sought to characterize patient engagement and experiences with cosmetic therapies for SSc‐related and non‐SSc–related facial changes.
Zachary Warren   +11 more
wiley   +1 more source

An Aggregate Measure for Benefit-Cost Analysis [PDF]

open access: yes
The Kaldor-Hicks (KH) criterion has long been the standard for benefit-cost analysis, but it has also been widely criticized for ignoring equity and, arguably, moral sentiments in general.
Finkle, Aaron   +2 more
core  

Validation of Patient‐Reported Outcomes Measurement Information System (PROMIS) Pediatric Measures for Children With Chronic Nonbacterial Osteomyelitis

open access: yesArthritis Care &Research, EarlyView.
Objective To assess the validity of the Patient‐Reported Outcomes Measurement Information System (PROMIS) Pediatric measures in patients with chronic nonbacterial osteomyelitis (CNO). Methods Within the longitudinal patient registry of CNO, English‐speaking patients aged 8 years and older self‐reported PROMIS Pediatric measures of fatigue, pain ...
Mary M. Eckert   +43 more
wiley   +1 more source

Home - About - Disclaimer - Privacy